Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Reconstructive Pelvic Anatomy classification system : a valid and reliable classification system for pelvic reconstruction.

Bone & joint open·2026

Same author

Pre-diagnostic route reported by patients with sarcoma from the Netherlands, the UK, Australia and New Zealand: early detection challenges for general practitioners - an international observational cohort study.

BMJ open·2026

Same author

A Systematic Review on the Role of Postoperative Radiotherapy in Pelvic Ewing Sarcoma.

Cancer medicine·2026

Same author

Efficacy and feasibility of treating adults with paediatric chemotherapy protocols in Ewing sarcoma, rhabdomyosarcoma and osteosarcoma - A systematic review by the Australia and New Zealand Sarcoma Association clinical practice guidelines working party.

Critical reviews in oncology/hematology·2026

Same author

International Dermoscopy Society consensus recommendations for the management of lentigo maligna.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026

Same author

Advanced Thymic Carcinoma Responds to Venetoclax and Azacitidine.

Clinical lung cancer·2026

Search research articles

Related Experiment Video

Updated: Mar 20, 2026

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma.

Georgia J B McCaughan¹, Michael J Fulham^1,2, Annabelle Mahar¹

¹Royal Prince Alfred Hospital, Camperdown, NSW, Australia.

Journal of Hematology & Oncology

|June 5, 2016

Summary

A patient with recurrent metastatic Ewing sarcoma (EWS) achieved remission with programmed cell death-1 (PD-1) blockade. This novel approach shows promise for EWS patients with poor prognoses.

Keywords:

Anti-programmed cell death-1 antibody Case report Ewing sarcoma Immunotherapy

More Related Videos

A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation

A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation

Published on: June 8, 2018

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Related Experiment Videos

Last Updated: Mar 20, 2026

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation

A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation

Published on: June 8, 2018

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Area of Science:

Oncology
Immunotherapy

Background:

Ewing sarcoma (EWS) is a rare bone and soft tissue cancer.
Recurrent or metastatic EWS carries a poor prognosis despite conventional therapies.
Genomic instability and PD-L1 expression in EWS suggest potential for immunotherapy.

Observation:

A heavily pre-treated patient with recurrent metastatic EWS was treated with PD-1 blockade.
The patient experienced significant clinical and radiological remission.

Findings:

This case report is the first to demonstrate the efficacy of PD-1 blockade in Ewing sarcoma.
PD-1 blockade can induce remission in patients with advanced EWS.

Implications:

PD-1 blockade represents a potential new treatment strategy for recurrent or metastatic EWS.
Further clinical investigation of PD-1 blockade in EWS is warranted.
This approach may improve outcomes for patients with poor-prognosis EWS.